Auxilium announces primary endpoints met in Xiaflex study Auxilium announced that new and updated data were presented from its IMPRESS trials, the Phase 3 studies that assessed Xiaflex for the potential treatment of Peyronie's disease. An open-label baseline analysis from IMPRESS 3 showed a mean penile curvature deformity of 53 degrees and a mean PD symptom bother score of 7.3. In this study, both co-primary endpoints of change in PCD and PD symptom bother were met with statistical significance compared to baseline. The mean percent change in PCD was 34.4 percent and the mean change in PD symptom bother score was 3.3 from baseline.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.